Press Coverage

DealStreetAsia: China’s Fosun to buy remaining stake in Henlius Biotech, valuing drugmaker at $1.7b

Excerpt:“…last close. “Shareholders with blocking stakes would welcome an offer suggesting a 30-40% takeover premium,” Arun George, an analyst at SMARTKARMA had said when Henlius went into a trading halt. Henlius shares last traded on May 22, at HK$18.84, before the firm issued a trading halt…”

NS6 (Web Content – Asia-Pac. ex Japan)via Bloomberg • (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

NS6 (Web Content – Asia-Pac. ex Japan)